6月3日 - ** 生物技术公司Beam Therapeutics BEAM.O股价盘前上涨4.9%，至16.96美元。
** BEAM称美国FDA已授予其治疗镰状细胞病的实验性细胞疗法 "孤儿药称号"$(SCD)$
** FDA 授予孤儿药资格，以促进美国少于 20 万人患罕见病的药物开发。
** SCD 是一种严重的终身性疾病，由血红蛋白基因错误引起，血红蛋白用于红细胞在体内携带氧气。
** BEAM-101疗法目前正在一项早期研究中进行测试，有30名患者接受了治疗。
** 截至上次收盘，BEAM 年累计下跌 34.7
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.